Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Toujeo and Tresiba on glucose time-in-range and variability in type 1 diabetes
2017-002756-91Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in diabetes mellitus type 1 (T1D) comparing Toujeo arm with Tresiba arm (2 arms). Primary endpoint: Time in glucose range 70–180 mg/dL at Week 12. Started Sep 2019; status: completed.
02
Drugs
insulin glargineinsulin degludec
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2017-002756-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002756-91.